Dr. Owen Garrick
Dr. Garrick joins Amarantus with over 20 years of pharmaceutical and biotechnology experience. He currently serves as the Chief Operating Officer at Bridge Clinical Research and is President of the American Medical Association Foundation. Prior to that, he was Director of Corporate Strategy and Business Development at McKesson Corporation. Dr. Garrick was Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals where he oversaw company acquisitions, hybrid equity/license rights deals, mature product divestments and venture investments in biotechnology companies. Prior to Novartis, Dr. Garrick was an associate at Goldman Sachs in New York. Dr. Garrick received his MD from Yale School of Medicine and earned his MBA from Wharton School of Business. He holds an AB from Princeton University, where he has served on the national fund raising board.
Dr. Colin Bier
Corporate Advisor and Chief Development Officer, Amarantus Diagnostics
Dr. Bier is managing and scientific director of ABA BioResearch, an independent bioregulatory consulting company providing expertise for technology assessment, fairness evaluation, due diligence and technical representation. Dr. Bier has extensive regulatory experience in the strategic management and development of pharmaceuticals, biopharmaceuticals, medical devices and diagnostics. Dr. Bier received his doctorate in experimental pathology from Colorado State University in 1978 and then pursued additional training as a Medical Research Council Postdoctoral Fellow and the Dr. Douglas James Fellow in the Department of Pathology, McGill University. Dr. Bier has extensive management experience in the biomedical sector having held senior scientific and executive management positions in the contract research industry as well as private industry and is a Senior Advisor to several venture funds and global biopharmaceutical companies. Dr. Bier is Chairman of the Advisory Committee for Technology Transfer of the Jewish General Hospital in Montreal, is on the scientific advisory board of three companies and serves as a director of two private companies and is a member of the Board of Trustees of Mount Sinai Hospital in Montreal, Canada. Dr. Bier will be working closely with Dr. Adam Simon, current member of the Company's Corporate Advisory Board, to finalize and implement the Company's commercialization strategy for LymPro to both maximize potential revenue and position LymPro as a potential companion diagnostic for therapeutic Alzheimer's programs.
Dr. Adam J. Simon
Dr. Simon is the founder and president of AJ Simon Enterprises, LLC, a consulting firm serving pharmaceutical and biotechnology clients, including Bristol Myers Squibb. He is also the founder and Chief Executive Officer of Cerora, Inc., a healthcare information technology company focused on developing medical devices and services to assess brain health, including Traumatic Brain Injury. Earlier in his career, Dr. Simon spent more than 13 years at Merck Research Laboratories, where he served as a Senior Research Fellow in Integrative Systems Neuroscience and Biomarkers and in Alzheimer's disease research. He has also been a visiting scientist at Princeton University. Dr. Simon received Bachelor's degrees in Physics and Mathematics from the University of Rochester. He received a Doctorate in Physics from the University of Chicago. Dr. Simon holds four patents related to medical research, and has published more than 60 articles in scientific and medical journals.
Dr. Louis Kirby
Dr. Kirby, is a board certified neurologist, and is a specialist in the development of drugs, medical devices, and laboratory developed diagnostics. He previously founded Pivotal Research Centers, which became one of the nation's largest free-standing private clinical research operations, before being sold in 2005 to a public company. Dr. Kirby currently consults for various biotechnology and large pharmaceutical companies. Dr. Kirby previously worked as Chief Medical Officer at Provista Life Sciences developing blood based biomarkers for breast cancer and Alzheimer's disease. Dr. Kirby also previously served as Director and co-Chair at the Critical Path Institute, working with Alzheimer's and Parkinson's biomarkers in the regulatory arena, working as a liaison between academia, industry and the FDA/EMA (EMEA) where he assembled international expert panels and managed their deliberations. Currently, Dr. Kirby is co-founder of ZettaScience (ZettaScience.com), a mission-based science infrastructure company offering a global scientific data search engine for researchers at universities, government and industry that promotes deeper scientific collaboration on pressing global challenges. Dr. Kirby sits on the Board of Directors of the Southwest Autism Research and Resource Center (SARRC) and chairs their Medical Research committee. Dr. Kirby is also an author, writing science-based thrillers including Shadow of Eden, a medical and political thriller that currently is an Amazon bestseller. Dr. Kirby obtained his undergraduate degree in honors Liberal Arts at University of Texas (Austin) and his medical degree from the University of Texas (Galveston).